Under the multi-year collaboration agreement, Guardant and Pfizer aim to:
- Utilize Guardant’s portfolio of liquid biopsy tests in Pfizer’s global clinical studies.
- Evaluate the clinical utility of (a) circulating tumor DNA (ctDNA) level as a surrogate endpoint to monitor therapy response and (b) related blood-based epigenomic analyses.
The collaboration will also allow Pfizer to access Guardant’s liquid biopsy tests in China for its global clinical trials, which include China cohorts.
In July 2022, Guardant announced a strategic partnership with Adicon Holdings Limited, an independent clinical laboratory company based in China, to offer Guardant tests to biopharmaceutical companies conducting clinical trials in China.
Guardant Reveal, which runs on Guardant’s Smart Liquid Biopsy platform, is a blood test that uses epigenomic (methylation) analysis to detect circulating tumor DNA (ctDNA), a marker of minimal residual disease (MRD). This test predicts cancer recurrence, helping to guide clinical decisions after surgery or chemotherapy.
Price Action: GH stock is up 2.59% at $46.82 at the last check Thursday.
Read Next:
Photo by Aunt Spray via Shutterstock
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
